Phase Ib/II Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
The purpose of this study is to assess the safety/tolerability/feasibility of pembrolizumab and radiation therapy before surgical resection in patients with recurrent glioblastoma as defined by treatment-related AEs and the number of patients who do not necessitate a delay in surgical resection, and to assess overall survival. The secondary objectives are to assess progression free survival, and to assess the T cell clonality, CD8 T cell activation and Tumor Infiltrating Lymphocyte (TIL) score after treatment
• Age 18 years or older
• Confirmed histologic diagnosis of WHO Grade IV, Glioblastoma Multiforme
• GBM recurrence or progression with planned standard of care surgical resection and repeat radiation
• Tumor size less than 6 cm
• ECOG performance status of 0-1
• Adequate laboratory values